Business
Appointment of corporate broker
Appointment of corporate broker.
About this update from Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 0217Y IP Group PLC 03 May 2019 \n\n\n\n\nFOR RELEASE ON\n\n\n3 May 2019\n\n\n\n \nIP Group plc - Appointment of corporate broker\n \nIP Group plc (LSE: IPO) (\"IP Group\" or \"the Group\" or \"the Company\"), the developer of intellectual property-based businesses, announces the appointment of Bank of America Merrill Lynch as corporate broker alongside Numis Securities Limited and Berenberg with immediate effect. \n \nFor more information, please contact:\n \n\n\n\nIP Group plc\n\n\nwww.ipgroupplc.com\n\n\n\n\nAlan Aubrey, Chief Executive Officer\nGreg Smith, Chief Financial Officer\nLiz Vaughan-Adams, Communications \n\n\n+44 (0) 20 7444 0050\n\n+44 (0) 20 7444 0062/+44 (0) 7979 853802\n\n\n\n\nCharlotte Street Partners\n\n\n\n\n\n\n\nDavid Gaffney\n\n\n+44 (0) 7854 609998\n\n\n\n\nAndrew Wilson\n\n\n+44 (0) 7810 636995\n\n\n\n \nNotes for editors\n \nAbout IP Group\n \nIP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.\n \nENDS\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END APPLIFVTEEIVIIA\n ","length":4860,"tagName":"div"}]